WO2003025579A3 - Use of heart fatty acid binding protein - Google Patents

Use of heart fatty acid binding protein Download PDF

Info

Publication number
WO2003025579A3
WO2003025579A3 PCT/EP2002/010488 EP0210488W WO03025579A3 WO 2003025579 A3 WO2003025579 A3 WO 2003025579A3 EP 0210488 W EP0210488 W EP 0210488W WO 03025579 A3 WO03025579 A3 WO 03025579A3
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
binding protein
acid binding
heart fatty
heart
Prior art date
Application number
PCT/EP2002/010488
Other languages
French (fr)
Other versions
WO2003025579A2 (en
Inventor
Volker Roenicke
Barbara Nave
Thomas Henkel
Joachim Beck
Original Assignee
Medigene Ag
Volker Roenicke
Barbara Nave
Thomas Henkel
Joachim Beck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag, Volker Roenicke, Barbara Nave, Thomas Henkel, Joachim Beck filed Critical Medigene Ag
Publication of WO2003025579A2 publication Critical patent/WO2003025579A2/en
Publication of WO2003025579A3 publication Critical patent/WO2003025579A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Animal Behavior & Ethology (AREA)

Abstract

The present invention relates to methods of identifying and/or obtaining a compound which is suspected to be an inhibitor or antagonist of H-FABP. Furthermore, pharmaceutical and diagnostic compositions are disclosed which are, inter alia, to be employed in diseases related to hypertrophy of cells.
PCT/EP2002/010488 2001-09-18 2002-09-18 Use of heart fatty acid binding protein WO2003025579A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32325101P 2001-09-18 2001-09-18
US60/323,251 2001-09-18
US32392101P 2001-09-21 2001-09-21
US60/323,921 2001-09-21

Publications (2)

Publication Number Publication Date
WO2003025579A2 WO2003025579A2 (en) 2003-03-27
WO2003025579A3 true WO2003025579A3 (en) 2003-12-04

Family

ID=26983850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010488 WO2003025579A2 (en) 2001-09-18 2002-09-18 Use of heart fatty acid binding protein

Country Status (1)

Country Link
WO (1) WO2003025579A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1605262A1 (en) * 2001-09-27 2005-12-14 Board Of Regents The University Of Texas System Method of identifying inhibitors of cardiac hypertrophy
WO2009149931A2 (en) * 2008-06-11 2009-12-17 Technische Universität Dresden Fatty acid binding protein in the pathogenesis of cardiac dysfunction
KR102287725B1 (en) * 2014-10-31 2021-08-06 삼성바이오에피스 주식회사 Production of a Recombinant Polypeptide by Overexpression of fatty acid binding protein
US20220152212A1 (en) * 2019-02-04 2022-05-19 Trait Biosciences, Inc. Systems, Methods, And Compositions For The Generation Of Water-Soluble Cannabinoids Utilizing Fatty-Acid Binding Proteins And Fatty-Acid Binding-Like Proteins As Cannabinoid-Carriers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232291B1 (en) * 1996-03-19 2001-05-15 Human Genome Sciences, Inc. Cytostatin III

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232291B1 (en) * 1996-03-19 2001-05-15 Human Genome Sciences, Inc. Cytostatin III

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BURTON P B J ET AL: "Heart fatty acid binding protein is a novel regulator of cardiac myocyte hypertrophy.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 205, no. 3, 1994, pages 1822 - 1828, XP002231467, ISSN: 0006-291X *
DATABASE EMBL [online] 1 November 1988 (1988-11-01), XP002232113, retrieved from EBI Database accession no. P05413 *
DATABASE EMBL [online] 24 December 2000 (2000-12-24), NIH-MGC, XP002231473, retrieved from EBI Database accession no. BF672001 *
DATABASE EMBL [online] 29 July 1986 (1986-07-29), NAKAMURA, Y, XP002231476, retrieved from EBI Database accession no. C02899 *
DATABASE EMBL [online] HILLIER ET AL., XP002231474, retrieved from EBI Database accession no. W25671 *
DATABASE EMBL [online] HILLIER ET AL., XP002231475, retrieved from EBI Database accession no. AA044151 *
OHKARU Y ET AL: "Development of a sandwich enzyme-linked immunosorbent assay for the determination of human heart type fatty acid-binding protein in plasma and urine by using two different monoclonal antibodies specific for human heart fatty acid-binding protein", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 178, no. 1, 13 January 1995 (1995-01-13), pages 99 - 111, XP004021129, ISSN: 0022-1759 *
ROHDE SHIRA ET AL: "The alpha1-adrenoceptor subtype- and protein kinase C isoform-dependence of norepinephrine's actions in cardiomyocytes.", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 32, no. 7, July 2000 (2000-07-01), pages 1193 - 1209, XP002231486, ISSN: 0022-2828 *
WU A H B: "ANALYTICAL AND CLINICAL EVALUATION OF NEW DIAGNOSTIC TESTS FOR MYOCARDIAL DAMAGE", CLINICA CHIMICA ACTA, AMSTERDAM, NL, vol. 272, no. 1, April 1998 (1998-04-01), pages 11 - 21, XP000944039, ISSN: 0009-8981 *

Also Published As

Publication number Publication date
WO2003025579A2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2005003732A3 (en) Diagnostic test for analytes in a sample
NO20013770L (en) Methods and compositions to increase the number of white blood cells
AU2003284002A1 (en) Kinematic and deformation analysis of 4-d coronary arterial trees reconstructed from cine angiograms
PT1366018T (en) Omega-aminoalkylamides of (r)-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
AU2003245689A1 (en) Method for testing the integrity of dpf's
ID29256A (en) CATALYST OF COMPLEXIVE OXIDE AND THE PROCESS OF MAKING ACRYLIC ACID
WO2000073452A3 (en) Compositions and methods for the treatment of immune related diseases
AU2003290605A1 (en) Compositions and methods for the diagnosis and treatment of sepsis
WO2004047792A3 (en) Liposomal glucocorticoids
AU2003222083A1 (en) Acid and ester compounds and methods of using the same
WO1999064001A3 (en) Methods and compositions for increasing penetration of hiv protease inhibitors
AU2003212245A1 (en) Method of diagnosis of inflammatory diseases using calgranulin c
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2003025579A3 (en) Use of heart fatty acid binding protein
WO2004107958A3 (en) Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
DE502004003952D1 (en) ENZYMATIC PREPARATION OF (METH) ACRYLIC ACID ESTERS
ID27000A (en) PROCESS FOR SEPARATION OF ENANSIOMER-ENANSIOMER 3 (R) -AND 3 (S) -HYDROCYSI-1-METHYL-4 (2,4,66-TRYMETHOPHENPHENYL) -1,2,3,6-TETRAHIDROPIRIDINE OR CARBOXICYLIC ACID ESTERS
WO2003001182A3 (en) Homocysteinylated transthyretin
AU2003287584A1 (en) Conjugated fatty acid based emulsion and methods for preparing and using same
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
EA200501231A1 (en) APPLICATION OF DIPYRIDAMOL IN COMBINATION WITH ACETYLSALICYLIC ACID AND ANTAGONIST ANGIOTENZIN II FOR PREVENTION OF STROKE
AU2003271733A1 (en) Method for determining the quantity of polymer separated from (meth)acrylic acid and/or (meth)acrylic acid esters
WO2005058314A3 (en) Methods for reducing the effects of stress on skin condition
WO2005019471A3 (en) Periostin-like factor: compositions and methods for making and using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP